Axonics reports second quarter 2023 financial results

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended june 30, 2023. “our commercial team continues to execute at a high level, generating revenue growth of 35% year over year in the second quarter,” said raymond w. cohen, chief executive officer. “our growth was driven by higher utiliza.
AXNX Ratings Summary
AXNX Quant Ranking